Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 EV-to-FCF is 2.43 as of Aug. 21, 2026, which is 83% below its 10-year median of 14.09. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 557 Drug Manufacturers companies, Korea United Pharm ranks better than 92.46% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Korea United Pharm's Enterprise Value is ₩94,954 Mil.
Korea United Pharm's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₩39,054 Mil. Therefore, Korea United Pharm's EV-to-FCF for today is 2.43.
The historical rank and industry rank for Korea United Pharm's EV-to-FCF or its related term are showing as below:
XKRX:033270'
s EV-to-FCF Range Over the Past 10 Years
Min: -480.31 Med: 14.09 Max: 5927.26
Current: 2.52
During the past 13 years, the highest EV-to-FCF of Korea United Pharm was 5927.26. The lowest was -480.31. And the median was 14.09.
XKRX:033270's EV-to-FCF is ranked better than 92.46% of 557
companies
in the Drug Manufacturers industry
Industry Median: 20.8
vs XKRX:033270: 2.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Korea United Pharm (XKRX:033270) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Korea United Pharm's PE Ratio (TTM) for today is calculated as:
Korea United Pharm's share price for today is ₩17910.00.
Korea United Pharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4923.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Korea United Pharm EV-to-FCF Related Terms
Korea United Pharm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's EV-to-FCF falls into.
Korea United Pharm's current Enterprise Value is ₩94,954 Mil.
Korea United Pharm's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩39,054 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a EV-to-FCF of 2.43 as of Aug. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Korea United Pharm and its competitors. This is 83% below median its historical median of 14.09. According to the industry distribution chart, Korea United Pharm ranks #42 out of 557 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Korea United Pharm's EV-to-FCF too high?
Korea United Pharm's current EV-to-FCF of 2.43 is 83% below median its 10-year median of 14.09. The Drug Manufacturers industry median EV-to-FCF is 20.80. Korea United Pharm's value of 2.43 is 88.3% below this industry median. Based on the distribution chart, Korea United Pharm ranks #42 out of 557 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #42 out of 557 companies for EV-to-FCF. This places Korea United Pharm in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.80. Korea United Pharm's value of 2.43 is 88.3% below this benchmark. While the company's 10-year median is 14.09 vs. the industry median of 20.80, Korea United Pharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.80, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current EV-to-FCF of 2.43 is 88.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current EV-to-FCF is 2.43, which is 83% below median its own 10-year median of 14.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current EV-to-FCF is 2.43, which is 83% below median its 10-year median of 14.09 and 88.3% below the Drug Manufacturers industry median of 20.80. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current EV-to-FCF is 2.43 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
EV-to-FCF: 2.43 (83% below median its 10-year median of 14.09)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 88.3% below the Drug Manufacturers median (#42 of 557)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
